Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 16, 2024 (filed on Apr 17, 2024)Insider Name:Jordan EricaOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,392Price:$3.80
-
Mar 18, 2024 (filed on Mar 19, 2024)Insider Name:Sjuts Dustin SOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-9,211Price:$5.04
-
Mar 18, 2024 (filed on Mar 19, 2024)Insider Name:Moxie DwightOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-8,125Price:$5.04
-
Mar 18, 2024 (filed on Mar 19, 2024)Insider Name:Schilke TobinOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-9,361Price:$5.04
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Sjuts Dustin SOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-2,967Price:$5.31
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Moxie DwightOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-3,269Price:$5.31
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Schilke TobinOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-3,822Price:$5.31
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Foley Mark JOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-17,228Price:$5.31
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Foley Mark JOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-3,305Price:$5.31
-
Mar 06, 2024 (filed on Mar 08, 2024)Insider Name:Foley Mark JOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:30,000Price:$6.98
Filings by filing date
-
Apr 16, 2024 (filed on Apr 17, 2024)Insider Name:Jordan EricaOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-2,392Price:$3.80
-
Mar 18, 2024 (filed on Mar 19, 2024)Insider Name:Sjuts Dustin SOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-9,211Price:$5.04
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Sjuts Dustin SOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-2,967Price:$5.31
-
Mar 18, 2024 (filed on Mar 19, 2024)Insider Name:Moxie DwightOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-8,125Price:$5.04
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Moxie DwightOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-3,269Price:$5.31
-
Mar 18, 2024 (filed on Mar 19, 2024)Insider Name:Schilke TobinOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-9,361Price:$5.04
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Schilke TobinOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-3,822Price:$5.31
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Foley Mark JOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-17,228Price:$5.31
-
Mar 15, 2024 (filed on Mar 19, 2024)Insider Name:Foley Mark JOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:F - Payment of exercise price or tax liability, exercise or vesting of a security under Rule 16b-3# or value acquired/disposed of:-3,305Price:$5.31
-
Mar 06, 2024 (filed on Mar 08, 2024)Insider Name:Foley Mark JOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:P - Open market or private purchase# or value acquired/disposed of:30,000Price:$6.98
News
Biz Brief
Sector: Healthcare | Industry: Pharmaceuticals |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 1222 Demonbreun Street, Suite 2000 NASHVILLE TN 37203 |
Tel: | 1-510-2796886 |
Website: | https://www.revance.com |
IR: | See website |
Key People | ||
Mark J. Foley Chief Executive Officer, Director | Tobin C. Schilke Chief Financial Officer | David A. Hollander Chief Medical Officer, Global Therapeutics Franchise Lead |
Erica Jordan Chief Commercial Officer | Dwight Moxie Chief Legal Officer |
Business Overview |
Revance Therapeutics, Inc. is a biotechnology company focused on developing and commercializing aesthetic and therapeutic offerings. The Company's portfolio includes DAXXIFY (DaxibotulinumtoxinA-lanm) for injection and the RHA Collection of dermal fillers in the United States. It has also partnered with Viatris to develop a biosimilar to onabotulinumtoxinA for injection and Fosun to commercialize DAXXIFY in China. Its product/product candidate includes DAXXIFY for glabellar lines indication; DAXXIFY for cervical dystonia indication; RHA Redensity for perioral rhytids indication; RHA 2/ RHA 3/ RHA 4 for facial wrinkles and folds (such as nasolabial folds) indication; DAXXIFY for forehead lines, lateral canthal lines, upper facial lines indication; DAXXIFY for upper limb spasticity indication, and onabotulinumtoxinA biosimilar. The Company has exclusive right to import, market, promote, sell and distribute Teoxane's line of Resilient Hyaluronic Acid dermal fillers. |
Financial Overview |
For the fiscal year ended 31 December 2023, Revance Therapeutics Inc revenues increased 77% to $234M. Net loss decreased 9% to $324M. Revenues reflect Product revenue increase of 80% to $212.7M, Service revenue increase of 75% to $12.2M, Collaboration revenue increase of 23% to $9.1M. Lower net loss reflects Amortization decrease of 78% to $6.1M (expense), Research & Development balance decrease of 22% to $65.5M (expense). |
Employees: | 534 as of Dec 31, 2022 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $549.88M as of Dec 31, 2023 |
Annual revenue (TTM): | $234.04M as of Dec 31, 2023 |
EBITDA (TTM): | -$207.03M as of Dec 31, 2023 |
Net annual income (TTM): | -$323.99M as of Dec 31, 2023 |
Free cash flow (TTM): | -$223.46M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $177.83M as of Dec 31, 2023 |
Shares outstanding: | 104,215,614 as of Mar 8, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |